Jubilant Organosys, through its subsidiary Jubilant Biosys Ltd, has signed a drug discovery partnership agreement with Amgen Inc, to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas.
Under the agreement, Jubilant will develop early pre-clinical candidates emanating from Amgen's early discovery efforts for an initial term of three years. Amgen will have responsibility for the subsequent pre-clinical and clinical development and commercialization. Amgen will retain/own the drugs developed under the collaboration with worldwide commercialization rights. Jubilant Biosys will partner in early-preclinical development effort from its state-of-the-art Jubilant Research Centre, Bangalore, while Amgen will pursue later stage pre-clinical and clinical development and commercialization of the drugs in global markets.
The details can be read here.
No comments:
Post a Comment